Experimental drug leniolisib targets immune dysregulation in rare disorders
NCT ID NCT06549114
First seen Feb 16, 2026 · Last updated May 17, 2026 · Updated 10 times
Summary
This study tests a drug called leniolisib in 12 people aged 12 to 75 with certain primary immunodeficiency disorders that cause immune system problems. The main goal is to see if the drug is safe and tolerable, and to explore how well it works at different doses. Participants will receive increasing doses of the drug, and researchers will monitor side effects and measure drug levels in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNODEFICIENCY DISORDERS (PIDS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institute of Health
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.